HC Wainwright Cuts Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $27.00

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective cut by research analysts at HC Wainwright from $28.00 to $27.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 111.60% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. decreased their price target on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Thursday, February 8th. StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, April 6th. Finally, JMP Securities cut their price target on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a report on Tuesday. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Enanta Pharmaceuticals has an average rating of “Hold” and a consensus price target of $19.00.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $12.76 on Tuesday. The stock has a market capitalization of $269.95 million, a P/E ratio of -2.04 and a beta of 0.54. The business has a 50 day simple moving average of $14.88 and a 200 day simple moving average of $12.08. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $28.25.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Equities analysts expect that Enanta Pharmaceuticals will post -4.9 earnings per share for the current year.

Institutional Trading of Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its position in shares of Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 2,281 shares during the last quarter. Clearstead Advisors LLC purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at $57,000. Quantbot Technologies LP lifted its stake in Enanta Pharmaceuticals by 2,300.0% during the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 6,900 shares in the last quarter. Sherbrooke Park Advisers LLC purchased a new position in Enanta Pharmaceuticals during the 3rd quarter worth $113,000. Finally, Laurion Capital Management LP bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter worth $126,000. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.